These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

847 related items for PubMed ID: 31279641

  • 1. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [Abstract] [Full Text] [Related]

  • 8. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
    Rrapaj E, Giacometti L, Spina P, Salvo M, Baselli GA, Veggiani C, Rena O, Trisolini E, Boldorini RL.
    Pathology; 2021 Jun; 53(4):462-469. PubMed ID: 33272690
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D.
    Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
    [Abstract] [Full Text] [Related]

  • 13. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G.
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M.
    Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
    [Abstract] [Full Text] [Related]

  • 16. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
    Otsubo K, Sakai H, Kimura H, Miyazawa T, Marushima H, Kojima K, Furuya N, Mineshita M, Chosokabe M, Koike J, Saji H.
    Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
    [Abstract] [Full Text] [Related]

  • 17. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A.
    Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
    [Abstract] [Full Text] [Related]

  • 18. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
    Gutierrez-Sainz L, Cruz P, Martinez-Recio S, Higuera O, Esteban-Rodriguez MI, Arias-Lotto F, Gonzalez RA, De Castro-Carpeño J.
    Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
    [Abstract] [Full Text] [Related]

  • 19. Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma.
    Lee HS, Hamaji M, Palivela N, Jang HJ, Splawn T, Ramos D, Lee AK, Raghuram AC, Ramineni M, Amos CI, Ripley RT, Burt BM.
    Ann Thorac Surg; 2021 Nov; 112(5):1575-1583. PubMed ID: 33248997
    [Abstract] [Full Text] [Related]

  • 20. c-Met expression and MET amplification in malignant pleural mesothelioma.
    Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC.
    Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.